Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review)
- Authors:
- Oana Alexandra Ciobanu
- Sorina Martin
- Simona Fica
-
Affiliations: Department of Endocrinology and Diabetes, Elias Hospital, 011461 Bucharest, Romania - Published online on: October 25, 2021 https://doi.org/10.3892/etm.2021.10914
- Article Number: 1479
-
Copyright: © Ciobanu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Klöppel G: Neuroendocrine neoplasms: Dichotomy, origin and classifications. Visc Med. 33:324–330. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Oberg K, Modlin IM, de Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, et al: Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 16:e435–e446. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Cheung VTF and Khan MS: A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline Gastroenterol. 6:264–269. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM and Castaño JP: Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord. 19:179–192. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV and Kidd M: Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 17:2427–2443. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Zatelli MC, Grossrubatscher EM, Guadagno E, Sciammarella C, Faggiano A and Colao A: Circulating tumor cells and mirnas as prognostic markers in neuroendocrine neoplasms. Endocr Relat Cancer. 24:R223–R237. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sechidis K, Papangelou K, Metcalfe PD, Svensson D, Weatherall J and Brown G: Distinguishing prognostic and predictive biomarkers: An information theoretic approach. Bioinformatics. 34:3365–3376. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lloyd RV, Osamura RY, Klöppel G and Rosai J (eds): WHO Classification of Tumours of Endocrine Organs. 4th edition, Volume 10. Lloyd RV, Osamura RY, IARC, 2017. | |
|
Rindi G, Klimstra DS, Abedi-Ardekani B, Brambilla E, Asa LS, Bosman TF, Busam JK, Dietel M, Fernandez-Cuesta L, Sasano H, et al: A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 31:1770–1786. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA: WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Rindi G and Inzani F: Neuroendocrine neoplasm update: Toward universal nomenclature. Endocr Relat Cancer. 27:R211–R218. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW and Feelders RA: Neuroendocrine neoplasms: Current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer. 26:R157–R179. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Rindi G, Klöpper G, Alhman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, et al: TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 449:395–401. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Rindi G, Klöpper G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 451:757–762. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Cho JH, Ryu JK, Song SY, Hwang JH, Lee DK, Woo SM, Joo YE, Jeong S, Lee SO, Park BK, et al: Prognostic validity of the American joint committee on cancer and the European neuroendocrine tumors staging classifications for pancreatic neuroendocrine tumors: A retrospective nationwide multicenter study in South Korea. Pancreas. 45:941–946. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Strosberg JR, Cheema A, Weber J, Han G, Coppola D and Kvols LK: Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 29:3044–3049. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler WM, Capella C, Caplin M, Couvelard A, Doglioni C, et al: TNM staging of neoplasms of the endocrine pancreas: Results from a large international cohort study. J Natl Cancer Inst. 104:764–777. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer. 113:5–21. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Flemming JB, Vauthey IN, Rashid A and Evans DB: One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 26:3063–3072. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National cancer registry of Spain (RGETNE). Ann Oncol. 21:1794–1803. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Ercolani G, Giuliante F, Ferrero A, Torzilli G, Grazi GL, Ratti F, et al: A novel nomogram to predict the prognosis of patients undergoing liver resection for neuroendocrine liver metastasis: An analysis of the Italian neuroendocrine liver metastasis database. J Gastrointest Surg. 21:41–48. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, Wang JB, Chen QY, Lin M, Tu RH and Huang CM: A novel predictive model based on preoperative blood neutrophilto-lymphocyte ratio for survival prognosis in patients with gastric neuroendocrine neoplasms. Oncotarget. 7:42045–42058. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Villani V, Mahadevan KK, Ligorio M, Fernández-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, et al: Phosphorylated histone H3 (PHH3) is a superior proliferation marker for prognosis of pancreatic neuroendocrine tumors. Ann Surg Oncol. 23 (Suppl 5):S609–S617. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Moss SF, Chung DC, Jensen RT and Snyderwine E: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 100:1282–1289. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Turner GB, Johnston BT, McCance DR, McGinty A, Watson RGP, Patterson CC and Ardill JE: Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 55:1586–1591. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L and Kidd M: Neuroendocrine tumor biomarkers: Current status and perspectives. Neuroendocrinology. 100:265–277. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, et al: Future directions in the treatment of neuroendocrine tumors: Consensus report of the National cancer institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol. 29:934–943. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, et al: Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 146:56–73. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Majala S, Seppänen H, Kemppainen J, Sundström J, Shalin-Jäntti C, Gullichsen R, Schildt J, Mustonen H, Vesterinen T, Arola J and Kauhanen S: Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT. EJNMMI Res. 9(116)2019.PubMed/NCBI View Article : Google Scholar | |
|
Bodei L, Sundin A, Kidd M, Prasad V and Modlin IM: The status of neuroendocrine tumor imaging: From darkness to light? Neuroendocrinology. 101:1–17. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G and Pappotti M: Somatostatin receptor tissue distribution in lung neuroendocrine tumours: A clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol. 21:548–555. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Reubi JC, Waser B, Cescato R, Gloor B, Stettler C and Christ E: Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab. 95:2343–2350. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO, Borg P, et al: Value of tumor growth rate (TGR) as an early biomarker predictor of patients' outcome in neuroendocrine tumors (NET)-The GREPONET Study. Oncologist. 24:e1082–e1090. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Bezerra ROF, et al: Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: The GREPONET-2 study. Clin Cancer Res. 25:6692–6699. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar | |
|
De Rubis G, Rajeev Krishnan S and Bebawy M: Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 40:172–186. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K and Modlin IM: The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci. 65:18–29. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G and Borson-Chazot F: Interest of chromogranin a for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 60:644–652. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Baekdal J, Krogh J, Klose M, Holmager P, Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF, et al: Limited diagnostic utility of chromogranin A measurements in workup of neuroendocrine tumors. Diagnostics (Basel). 10(881)2020.PubMed/NCBI View Article : Google Scholar | |
|
Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D and Kountourakis P: Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol. 7:9–15. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Malczewska A, Kidd M, Matar S, Kos-Kudła B, Bodei L, Oberg K and Modlin IM: An assessment of circulating chromogranin a as a biomarker of bronchopulmonary neuroendocrine Neoplasia: A systematic review and meta-analysis. Neuroendocrinology. 110:198–216. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L and degli Uberti EC: Italian CromaNet Working Group. Chromogranin A as a marker of neuroendocrine neoplasia: An Italian multicenter study. Endocr Relat Cancer. 14:473–482. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R and Tomassetti P: Chromogranin A: Is it a useful marker of neuroendocrine tumors? J Clin Oncol. 25:1967–1973. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Stridsberg M, Oberg K, Li Q, Engstrom U and Lundqvist G: Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 144:49–59. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S and Pavlakis N: Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol. 113:268–282. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, Rufflé P and Schlumberger M: Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12 Suppl. 2:S79–S82. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Hermann KA, Hoffmann JN, Spitzweg C, Göke B and Auernhammer CJ: Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: A single center experience and literature review. Cancers (Basel). 4:141–155. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Mashige F, Matsushimal Y, Kanazawal H, Sakuma I, Takai N, Besshof F and Ohkubo A: Acidic catecholamine metabolites and 5-hydroxyindoleacetic acid in urine: The influence of diet. Ann Clin Biochem. 33:43–49. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Feldman JM: Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem. 32:840–844. 1986.PubMed/NCBI | |
|
Sjöblom SM: Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol. 23:779–787. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD and Davar J: Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg. 40:168–172. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, et al: ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 103:125–138. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Korse CM, Taal BG, de Groot CA, Bakker RH and Bonfrer JM: Chromogranin-A and N-terminal pro-brain natriuretic peptide: An excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol. 27:4293–4299. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Bodei L and Kidd M: Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 30:59–77. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Bhattacharyya S, Toumpanakis C, Caplin ME and Davar J: Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 102:938–942. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Isgrò MA, Bottoni P and Scatena R: Neuron-specifi c enolase as a biomarker: Biochemical and clinical aspects. Adv Exp Med Biol. 867:125–143. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié P and Schlumberger M: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 78:1102–1107. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Walter T, Chardon L, Chopin-Laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY and Lombard-Bohas C: Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer. 48:1766–1773. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Laskaratos FM, Rombouts K, Caplin M, Toumpanakis C, Thirlwell C and Mandair D: Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer. 123:4770–4790. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Behnes M, Brueckmann M, Lang S, Weiß C, Ahmad-Nejad P, Neumaier M, Borggrefe M and Hoffmann U: Connective tissue growth factor (CTGF/CCN2): Diagnostic and prognostic value in acute heart failure. Clin Res Cardiol. 103:107–116. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Cunningham JL, Tsolakis AV, Jacobson A and Janson ET: Connective tissue growth factor expression in endocrine tumors is associated with high stromal expression of alpha-smooth muscle actin. Eur J Endocrinol. 163:691–697. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kidd M, Modlin I, Shapiro M, Camp R, Mane S, Usinger W and Murren J: CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol. 13:5208–5216. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Bellizzi AM: Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: What can brown do for you? Hum Pathol. 96:8–33. 2020.PubMed/NCBI View Article : Google Scholar | |
|
McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, et al: Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both ki67 Proliferative index and mitotic rate. Am J Surg Pathol. 37:1671–1677. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bellizzi AM: Pathologic considerations in gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 29:185–208. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Coriat R: Aggressive gastro-entero-pancreatic neoplasms. Ann Endocrinol (Paris). 80:185–186. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G and Wiedenmann B: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 113:256–265. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Strosberg J, Nasir A, Coppola D, Wick M and Kvols L: Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 40:1262–1268. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Lopez-Aguiar AG, Ethun CG, Postlewait LM, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Sarmiento JM, Kooby DA, Staley CA, et al: Redefining the Ki-67 index stratification for low-grade pancreatic neuroendocrine tumors: Improving its prognostic value for recurrence of disease. Ann Surg Oncol. 25:290–298. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zen Y and Heaton N: Elevated Ki-67 labeling index in ‘synchronous liver metastases’ of well differentiated enteropancreatic neuroendocrine tumor. Pathol Int. 63:532–538. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Grillo F, Albertelli M, Brisigotti MP, Borra T, Boschetti M, Fiocca R, Ferone D and Mastracci L: Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology. 103:452–459. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J and Liu EH: Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World health organization grade discordance with primary tumors. Am J Clin Pathol. 143:398–404. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Cives M and Strosberg JR: Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 68:471–487. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Singh S, Hallet J, Rowsell C and Law CH: Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol. 40:1517–1522. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Keck KJ, Choi A, Maxwell JE, Li G, O'Dorisio TM, Breheny P, Bellizzi AM and Howe JR: Increased grade in neuroendocrine tumor metastases negatively impacts survival. Ann Surg Oncol. 24:2206–2212. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, et al: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 24:152–160. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C and Öberg K: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 117:4617–4622. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Jiang R, Hong X, Zhao Y and Wu W: Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms. Cancer Lett. 499:39–48. 2021.PubMed/NCBI View Article : Google Scholar | |
|
van Riet J, van de Werken HJG, Cuppen E, Eskens FALM, Tesselaar M, van Veenendaal LM, Klümpen HJ, Dercksen MW, Valk GD, Lolkema MP, et al: The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nat Commun. 12(4612)2021.PubMed/NCBI View Article : Google Scholar | |
|
Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, et al: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 543:65–71. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Mafficini A and Scarpa A: Genomic landscape of pancreatic neuroendocrine tumours: The International cancer genome consortium. J Endocrinol. 236:R161–R167. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Scarpa A: The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Ann Endocrinol (Paris). 80:153–158. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, et al: Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg. 271:566–573. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, et al: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 25:1260–1265. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Marinoni I: Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: Is it time for clinical implementation? Gut gutjnl-2021-324664, 2021 (Epub ahead of print). | |
|
Lewis PW, Elsaesser SJ, Noh KM, Stadler SC and Allis CD: Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA. 107:14075–14080. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, Taylor S, Higgs DR and Gibbons RJ: Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun. 6(7538)2015.PubMed/NCBI View Article : Google Scholar | |
|
Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, et al: Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res. 23:600–609. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A and Berruti A: ESMO Guidelines Committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31:844–860. 2020.PubMed/NCBI View Article : Google Scholar | |
|
VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH and Heaphy CM: Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 125:544–551. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, et al: Altered telomeres in tumors with ATRX and DAXX mutations. Science. 333(425)2011.PubMed/NCBI View Article : Google Scholar | |
|
Luchini C, Lawlor RT, Bersani S, Vicentini C, Paolino G, Mattiolo P, Pea A, Cingarlini S, Milella M and Scarpa A: Alternative lengthening of telomeres (ALT) in pancreatic neuroendocrine tumors: Ready for prime-time in clinical practice? Curr Oncol Rep. 23(106)2021.PubMed/NCBI View Article : Google Scholar | |
|
Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL and Choti M: Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. J Am Coll Surg. 218:628–635. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, et al: Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut gutjnl-2020-322595, 2021 (Epub ahead of print). | |
|
Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, et al: Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res. 23:1598–1606. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ and Perren A: Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 146:453–460.e5. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, et al: Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 28:245–255. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Stevenson M, Lines KE and Thakker RV: Molecular genetic studies of pancreatic neuroendocrine tumors: New therapeutic approaches. Endocrinol Metab Clin North Am. 47:525–548. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zou Z, Tao T, Li H and Zhu X: mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci. 10(31)2020.PubMed/NCBI View Article : Google Scholar | |
|
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 331:1199–1203. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Coriat R, Walter T, Terris B, Couvelard A and Ruszniewski P: Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: Review and position statement. Oncologist. 21:1191–1199. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, Kobayashi N, Ikeda M, Ito T, Nakamori S, et al: Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: A Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res. 23:4625–4632. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, et al: Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS One. 12(e0187667)2017.PubMed/NCBI View Article : Google Scholar | |
|
Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL, et al: Poorly differentiated neuroendocrine carcinomas of the pancreas: A clinicopathologic analysis of 44 cases. Am J Surg Pathol. 38:437–447. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Scoazec JY: Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives? Ann Endocrinol (Paris). 80:163–165. 2019.PubMed/NCBI View Article : Google Scholar | |
|
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, et al: Comprehensive genomic profiles of small cell lung cancer. Nature. 524:47–53. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den Broek EC, Chabrier A, et al: Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 24:33–42. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ and Engstrom PF: Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: A fox chase cancer center pilot study. Br J Cancer. 115:564–570. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Chen C, Notkins AL and Lan MS: Insulinoma-associated-1: From neuroendocrine tumor marker to cancer therapeutics. Mol Cancer Res. 17:1597–1604. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tanigawa M, Nakayama M, Taira T, Hattori S, Mihara Y, Kondo R, Kusano H, Nakamura K, Abe Y, Ishida Y, et al: Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol. 51:32–40. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, et al: Insulinoma-associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer. Am J Pathol. 185:3164–3177. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, et al: ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 111:14788–14793. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wang H, Chen Y, Fernandez-Del Castillo C, Yilmaz O and Deshpande V: Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: A critical look at notch signaling pathway. Mod Pathol. 26:139–147. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Rodriguez EF, Fite JJ, Chowsilpa S and Maleki Z: Insulinoma-associated protein 1 immunostaining on cytology specimens: An institutional experience. Hum Pathol. 85:128–135. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Drozdov I and Kidd M: The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 8(63364)2013.PubMed/NCBI View Article : Google Scholar | |
|
Kidd M, Drozdov I and Modlin I: Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 22:561–575. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Genzen JR, Mohlman JS, Lynch JL, Squires MW and Weiss RL: Laboratory-developed tests: A legislative and regulatory review. Clin Chem. 63:1575–1584. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Aslanian H, Bodei L, Drozdov I and Kidd M: A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. Endocr Connect. 3:215–223. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR and Bodei L: Assessment of NETest clinical utility in a U.S. registry-based study. Oncologist. 24:783–790. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Malczewska A, Bodei L, Kidd M and Modlin IM: Blood mRNA measurement (NETest) for Neuroendocrine tumor diagnosis of image-negative liver metastatic disease. J Clin Endocrinol Metab. 104:867–872. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S and Chung KM: The NETest: The clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocrinol Metab Clin North Am. 47:485–504. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A and Paulson S: A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 31:202–212. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hackeng WM, Morsink FHM, Moons LMG, Heaphy CM, Offerhaus GJA, Dreijerink KMA and Brosens LAA: Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration. Diagn Cytopathol. 48:308–315. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR and Kebebew E: Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Semin Oncol. 45:232–235. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Demes M, Aszyk C, Bartsch H, Schirren J and Fisseler-Eckhoff A: Differential miRNA-Expression as an adjunctive diagnostic tool in neuroendocrine tumors of the lung. Cancers (Basel). 8(38)2016.PubMed/NCBI View Article : Google Scholar | |
|
Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM and Voinea SC: MiRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells. 9(276)2020.PubMed/NCBI View Article : Google Scholar | |
|
Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A and Croce CM: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 24:4677–4684. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Vicentini C, Fassan M, D'Angelo E, Corbo V, Silvestris N, Nuovo GJ and Scarpa A: Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. Molecules. 19:2458–2468. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Panarelli N, Tyryshkin K, Wong JJM, Majewski A, Yang X, Scognamiglio T, Kim MK, Bogardus K, Tuschl T, Chen YT and Renwick N: Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocr Relat Cancer. 26:47–57. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, et al: NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 39:735–752. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Reddy KB: MicroRNA (miRNA) in cancer. Cancer Cell Int. 15(38)2015.PubMed/NCBI View Article : Google Scholar | |
|
Cives M, Simone V, Rizzo FM and Silvestris F: NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget. 7:57414–57429. 2016.PubMed/NCBI View Article : Google Scholar | |
|
House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A and Yeo CJ: Aberrant hypermethylation tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 238:423–431; discussion 431-2. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Campana D, Walter T, Pusceddu S, Gelsomino F, Graillot E, Prinzi N, Spallanzani A, Fiorentino M, Barritault M, Dall'Olio F, et al: Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: An observational retrospective multicenter study. Endocrine. 60:490–498. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C, Joly MO and Scoazec JY: O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: Prognostic relevance and association with response to alkylating agents. Br J Cancer. 112:523–531. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Marzese DM, Hirose H and Hoon DS: Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 13:827–844. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 372:1689–1699. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Boons G, Vandamme T, Peeters M, Beyens M, Driessen A, Janssens K, Zwaenepoel K, Roeyen G, Van Camp G and Op de Beeck K: Cell-free DNA from metastatic pancreatic neuroendocrine tumor patients contains tumor-specific mutations and copy number variations. Front Oncol. 8(467)2018.PubMed/NCBI View Article : Google Scholar | |
|
Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 46:318–322. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Raptis L and Menard HA: Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest. 66:1391–1399. 1980.PubMed/NCBI View Article : Google Scholar | |
|
Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M and Meyer T: Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 17:337–345. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME and Meyer T: Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 31:365–372. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R, Hartley JA, Caplin ME and Meyer T: Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin Cancer Res. 22:79–85. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Childs A, Vesely C, Ensell L, Lowe H, Luong TV, Caplin ME, Toumpanakis C, Thirlwell C, Hartley JA and Meyer T: Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 115:1540–1547. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al: Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 20:716–731. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, et al: 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 37:1441–1448. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, et al: Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 59:66–74. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E and Lepareur N: Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 25(4012)2020.PubMed/NCBI View Article : Google Scholar | |
|
Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ III, Osborne JR and Dutruel SP: Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging. 56:146–154. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Graham MM, Gu X, Ginader T, Breheny P and Sunderland JJ: 68Ga-DOTATOC imaging of neuroendocrine tumors: A systematic review and metaanalysis. J Nucl Med. 58:1452–1458. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ and Kebebew E: Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 34:588–597. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D and Imperiale A: Molecular imaging of gastroenteropancreatic neuroendocrine tumors: Current status and future directions. J Nucl Med. 57:1949–1956. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M and Perren A: Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 36:48–52. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U and Giesel FL: SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 17:313–318. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, et al: Phase 3 trial of (177)Lu-Dotatate for Midgut Neuroendocrine tumors. N Engl J Med. 376:125–135. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nicolas G, Mansi R, Vomstein S, Kaufmann J, Bouterfa H, Maecke H, Wild D and Fani M: Wider safety window with radiolabeled somatostatin receptor antagonists over agonists. J Nucl Med. 56 (Suppl 3)(S335)2015. | |
|
Fani M, Nicolas GP and Wild D: Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 58 (Suppl 2):61S–66S. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T and Baum RP: Theranostic perspectives in prostate cancer with the Gastrin-Releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results. J Nucl Med. 58:75–80. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, Boucher E and Raoul JL: Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 50:858–864. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer HP, Simon B, Höller T, Biersack HJ and Nagarajah J: Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: Feasibility of a metabolic grading system. J Nucl Med. 55:1260–1266. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, et al: Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: Proposal for a novel grading scheme with prognostic significance. Theranostics. 7:1149–1158. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hindié E: The netpet score: Combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors. Theranostics. 7:1159–1163. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, et al: ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 103:172–185. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, et al: Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 58:91–96. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I and Rodrigues M: Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging. 43:1585–1592. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, et al: Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res. 20:246–252. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J and Kurzrock R: Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 30:2684–2690. 2012.PubMed/NCBI View Article : Google Scholar |
